AstraZeneca and CSPC to build biologics manufacturing plant in China. Lori Ellis Head of Insights | Biospace Patient Daily | Aug 10, 2026 AstraZeneca and CSPC Pharmaceutical announced on Aug. 10 a joint venture to construct a biologics manufacturing plant in Shijiazhuang, China. The collaboration is part of AstraZeneca's ongoing investment strategy in the country, which includes a commitment made in January to spend $15 billion by the end of the decade. Under the agreement, CSPC will hold a 51% equity stake while AstraZeneca will hold 49%. Both companies will contribute capital for the construction of the site located in Shijiazhuang, about 165 miles southwest of Beijing and home to CSPC's headquarters. The partners said they will jointly manage both construction and daily operations at the facility. AstraZeneca plans to leverage its global quality system and supply management experience for this project. CSPC highlighted its expertise in building "highly automated, intelligent and lean manufacturing facilities." Initially, production at the new site will focus on mutually agreed but undisclosed biologic drug substances intended for global markets. As business develops and demand grows, more products may be added to the facility's scope. According to CSPC, working with AstraZeneca supports creating high-quality manufacturing capabilities that meet international market demands. The partnership is expected to enhance CSPC's ability to serve global markets and support future overseas product launches. The joint venture expands an existing relationship between AstraZeneca and CSPC that has included several deals since 2024: $100 million upfront for rights to a preclinical lipid-lowering drug candidate; $110 million for an artificial intelligence drug development pact; $1.2 billion upfront for a GLP-1/GIP prospect; and $30 million for kidney disease collaboration. Beyond research partnerships, AstraZeneca has also invested in other Chinese facilities - including alliances with BioKangtai for vaccine production in Beijing, expansion projects such as an additional $136 million investment into Qingdao inhaled medicines plant, as well as establishing cell therapy capabilities with a new center under construction in Shanghai.

CSPC Pharmaceutical & AstraZeneca form joint venture for biologics manufacturing in China. CSPC Pharmaceutical and AstraZeneca have formed a 51:49 joint venture to build a biologics manufacturing facility in Shijiazhuang. CSPC Pharmaceutical Group and AstraZeneca have entered into a joint venture contract to build a new-generation biologics manufacturing facility in Shijiazhuang, China. The venture marks the third strategic agreement the two companies have struck in as many years, and is expected to focus on the manufacturing and supply of mutually agreed biologics drug substances for global markets, with the companies contributing capital at a 51:49 equity ratio in favor of CSPC.[1] What are the terms of the joint venture? Under the terms of the joint venture contract, CSPC and AstraZeneca will jointly manage construction along with day-to-day operations, drawing on their respective strengths. As the business develops, production capacity scales up, and commercial demand grows, the companies say they will explore incorporating additional products into the joint venture's scope.[1] The agreement remains subject to customary closing conditions, including regulatory approvals. The joint venture is designed to combine CSPC's AI-driven Good Manufacturing Practice system and its pharmaceutical manufacturing construction and operational capabilities with AstraZeneca's expertise in global quality standards and supply chain management.[1] The initial business scope centers on biologics drug substances, with both companies committing to delivering high-quality medicines to patients worldwide. Why does this matter for CSPC's global ambitions? CSPC says the collaboration reflects strong recognition of its modernized manufacturing system, quality management capabilities, and industrial-scale execution by a leading global multinational pharmaceutical company. The company frames the joint venture as extending its internationalization path from "going global with products and technologies" to "going global with manufacturing systems and supply chain capabilities."[1] As global pharmaceutical companies continue to optimize research, manufacturing, and supply chain footprints, CSPC argues that high-quality, efficient, and sustainable manufacturing and supply capabilities are becoming a core competency across the global innovative drug value chain, laying groundwork for more of its innovative drug products to enter international markets. Previous deals between CSPC and AstraZeneca. The manufacturing joint venture builds on a fast-deepening relationship between the two companies. In June 2025, AstraZeneca and CSPC entered a to discover and develop pre-clinical oral candidates against high-priority targets across multiple chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases.[2] The research is being carried out by CSPC in Shijiazhuang using its AI-driven, dual-engine drug discovery platform. As part of the agreement, CSPC received an upfront payment of $110 million and eligiblity for up to $1.62 billion in development milestone payments and upwards of $3.6 billion in sales milestone payments.[2] More recently, the companies struck a for obesity and type 2 diabetes across eight programs, four of which will progress initially using CSPC's AI-driven peptide drug discovery platform and its proprietary LiquidGel once-monthly dosing technology.[3] AstraZeneca secured exclusive global rights outside China to CSPC's once-monthly injectable weight management portfolio, including SYH2082, a long-acting GLP1R/GIPR agonist progressing into Phase I, and three preclinical programs.[3] What comes next? With the biologics manufacturing joint venture still pending regulatory clearance, CSPC says it believes the new facility will strengthen its ability to meet international manufacturing and supply demand while supporting the broader pipeline of products emerging from its expanding partnership with AstraZeneca.

How gamification can nudge employees to act more sustainably. Thousands of laboratories have joined a worldwide challenge to cut the energy used to power ultra-low temperature freezers. Key Takeaways: * The 2026 Freezer Challenge recognizes labs that tweak temperature settings and take other energy-saving steps. * AstraZeneca and Amgen are among the winners. * Gamification is used by the EPA, CDP and other organizations to motivate companies to act on sustainability. AstraZeneca and Amgen are among the winners of a competition that demonstrates how gamification can motivate companies and employees to tackle sustainability challenges. The two pharma giants were among more than 4,000 laboratories and close to 270 organizations that saved a total of almost 30 gigawatt hours (GWh) of energy by changing the way they operate and maintain freezers that store biological samples. Labs cut energy by setting freezers at slightly higher temperatures - minus 70 degrees Celsius rather than the industry standard of minus 80 degrees, a change that has no impact on most samples - and ensuring that freezer components are properly maintained. These steps can have meaningful impacts because lab freezers are "pretty significant energy hogs," said James Connelly, CEO of My Green Lab, which runs the 2026 Freezer Challenge and other initiatives designed to make laboratories more sustainable. A single ultra-low temperature freezer can use as much energy as two American homes, he estimated. (Raising the temperature of food storage freezers can also produce useful savings.) Amgen won the Top Organization Award by saving an average of 5,314 kWh per day during the first half of 2026, with U.K.-based AstraZeneca notching up daily savings of 5,244 kWh, earning it the Winning Streak Award for repeated high performance in the challenge, which launched in 2017. Siemens Healthineers, which operates in Canada, Ireland and the U.S., was named Top Organization in the hospital category, and the U.K.'s Institute of Cancer Research scooped the academic section. Gamification hack. Gamifying the energy savings is "one of the hacks we use to drive impact," said Connelly. "So much of sustainability these days is doom and gloom and compliance," he noted. Adding the awards and recognition pushes teams to do something that is already in their interest - saving energy and, thus, money - but which they might not otherwise act on. Sustainability professionals often say that company rankings can motivate C-suites and boards to fund projects, even if the competitions offer kudos rather than cash to winners. Influential competitions elsewhere in sustainability include CDP's Corporate A List, which recognizes companies that score highly for environmental transparency; the EPA's Green Power Partnership National Top 100, which ranks companies by clean power purchases (its status under the current U.S. administration is unclear); and the Global 100 list from media and research organization Corporate Knights. Get real case studies, expert action steps and the latest sustainability trends in a concise morning email. Jim Giles is Vice President, Editor-at-Large at Trellis Group. His writing has appeared in the New York Times, Atlantic, Economist, Guardian, Nature and other publications. He was the co-founder of Matter, an award-winning investigative publication that was acquired by Medium in 2013. In 2017, he was a graduate of the Sulzberger Executive Leadership Program at Columbia University. He's also worked as a strategic consultant for several high-impact organizations, including the European Climate Foundation and the Wellcome Trust.